CN112823667B - Application of the composition in preventing or alleviating colic in infants and young children - Google Patents

Abstract

The invention belongs to the field of food or medicine, and specifically discloses that the composition can be used in the preparation of food for preventing, reducing or alleviating intestinal colic in infants, medicine for preventing or treating intestinal colic in infants, or improving the symptoms of getting angry in infants and/or infants. The use in foods or medicines of lit behavior; wherein, the composition comprises palmitic acid glycerides, α-lactalbumin, β-casein and selected from Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium longum Bacillus, Bifidobacterium breve, Bifidobacterium adolescentis, Bifidobacterium bifidum, and Bifidobacterium infantis; wherein, calculated as palmitic acid, glyceryl palmitate contains more than 15% by weight of Sn‑ 2 glyceryl palmitate.

Description

Application of the composition in preventing or alleviating colic in infants and young children

technical field

The invention belongs to the field of food or medicine, and specifically relates to the application of the composition in preventing or alleviating intestinal colic in infants and young children.

Background technique

According to statistics, crying accounts for 20% of newborn pediatric consultations, and a large proportion of babies will experience abdominal discomfort symptoms such as colic within 3 months after birth, and among babies of different sexes and different feeding methods Colic occurred at a similar rate. Colic is usually benign and gradually disappears as the baby grows from 4 months onwards. Although infantile colic and its resulting night-time crying are self-limiting and benign, it often leads to exhaustion and even depressive illness for parents and caregivers. Therefore, there is an urgent need to find a method or product for effectively preventing or alleviating colic in infants.

Early in life, when both the gut and the brain undergo rapid changes, this is also a critical period for the colonization and formation of gut microbes. A range of factors have been found to influence gut microbiota composition early in life, including gestational age at birth, mode of delivery, feeding regime, genetic background, geographic environment, nursing mother's diet, and antibiotic use. Full-term delivery, natural vaginal delivery, and exclusive breastfeeding for 6 months after birth are favorable factors for the establishment and maturation of early gut microbiota, which can reduce the risk of some acute and chronic diseases, such as obesity, type 1 diabetes, allergies, and inflammatory bowel disease illness etc. Some studies have pointed out that colic infants have different gut microbiota than normal infants.

Breast milk fat provides 45% to 60% of the energy for early growth of infants, and more than 98% of breast milk fat is triglyceride. There are differences between different fatty acids in breast milk and glycerol esterification positions; among them, unsaturated fatty acids in breast milk such as linoleic acid and α-linolenic acid are mostly located in the 1st and 3rd positions of triglycerides; long-chain saturated fatty acids in breast milk For example, palmitic acid is mainly located at the 2 position, and the palmitic triglyceride formed in this way is called Sn-2 palmitic triglyceride. In the digestive tract, the lipolytic enzymes in the baby's stomach mainly act on the 1- and 3-position ester bonds of triglycerides. Therefore, unsaturated fatty acids are first freed, and then combined with Sn-2 monoglyceride palmitate in the duodenum be degraded and absorbed together. However, ordinary infant formula powder contains palm oil, and most of its long-chain saturated fatty acids are esterified in the 1- and 3-position ester bonds of triglycerides. After hydrolysis, it is easy to combine with calcium ions to form calcium soap, which reduces the fat and mineral content. At the same time, calcium soaps that are difficult to absorb may also make the stool hard and cause difficulty in defecation. The national standard GB14880 allows the addition of OPO structural esters in infant formula powder, which is a food raw material rich in Sn-2 palmitic acid triglycerides. Adding OPO structural esters can increase the proportion of Sn-2 palmitic triglycerides in the product. Compare.

Breast milk is rich in a-lactalbumin, a protein rich in essential amino acids, which can be digested to produce a variety of biologically active peptides. Studies have found that a-lactalbumin digestion products can inhibit pathogenic bacteria such as Escherichia coli, pneumococcus, Staphylococcus aureus and Candida in vitro.

β-casein is the most abundant casein molecule in breast milk, and the polypeptide fragments produced by digestion can inhibit the growth of harmful bacteria.

Probiotics are an important component of the gut microbiota. The World Food and Agriculture Organization (FAO) and the World Health Organization (WHO) define probiotics as: live bacteria that can exert an effective effect on the health of the eater through ingestion of an appropriate amount. Bifidobacterium genus is a kind of probiotics. Currently, common bifidobacterium strains include Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium infantis, etc., and some new strains.

Contents of the invention

The invention provides the application of the composition in preventing or relieving colic in infants, or improving the symptoms and/or angry behaviors of infants.

The present invention relates to the composition in the preparation of food for preventing, reducing or alleviating intestinal colic in infants, the medicine for preventing or treating intestinal colic in infants, or the food or medicine for improving the symptoms and/or behaviors of infants getting angry wherein, the composition comprises glyceryl palmitate, α-lactalbumin, β-casein and selected from Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium breve, youth At least one kind of Bifidobacterium bifidobacterium, Bifidobacterium bifidum and Bifidobacterium infantis; wherein, calculated according to palmitic acid, glyceryl palmitate contains more than 15% (such as more than 18%, more than 20%, 15% ~98%, 15%~90%, 20%~80%, 20%~95%, 30%, 40%, 50%, 60%, 70%) weight of Sn-2 glyceryl palmitate.

In some embodiments of the present invention, glyceryl palmitate includes glyceryl palmitate Sn-2 and optionally glyceryl palmitate other than Sn-2 glyceryl palmitate.

In some embodiments of the present invention, the weight ratio between α-lactalbumin, β-casein and Sn-2 glyceryl palmitate is (1-10):(1-10):(1-10), For example 1:(1-2):(1-2), 1:(1-5):(1-5), 1:(1-7):(1-7), 1:(1-6) :(1-6), 1:1.32:1.2, 1:1:1, 1:3:3, 1:5:5, 1:8:8.

In some embodiments of the present invention, the number of viable bifidobacteria is 10 ⁷ to 10 ¹³ CFU per gram of a-lactalbumin, such as 10 ⁸ CFU, 10 ⁹ CFU, 10 ¹⁰ CFU, 10 ¹¹ CFU, 10 ¹² CFU.

In some embodiments of the present invention, the Bifidobacterium is selected from Bifidobacterium BB12 and Bifidobacterium HN019.

In some embodiments of the present invention, the ratio of the viable count of Bifidobacterium BB12 to Bifidobacterium HN019 is (1:100)～(100:1), such as 100:1, 90:1, 80:1, 70: 1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 5:1, 1:1, 1:5, 1:8, 1:10, 1:14, 1:17, 1:20, 1:30, 1:40, 1:50, 1:60, 1:70, 1:80, 1:90.

In some embodiments of the present invention, the composition further comprises fats other than glyceryl palmitate.

In some embodiments of the present invention, fats other than glyceryl palmitate are commonly used fats in the art.

In some embodiments of the present invention, the fat other than glyceryl palmitate is selected from glyceryl linoleate, glyceryl linolenate, glyceryl docosahexaenoate and glyceryl arachidonic acid.

In some embodiments of the present invention, in the composition, based on fatty acid calculation, the weight of glyceryl palmitate accounts for 1% to 96% of the total weight of fat, such as 10% to 90%, 20% to 80%, and 30% to 70%. , 20% to 90%, 10% to 50%, 5% to 40%, 5% to 60%. Among them, fat is formed by combining fatty acids and glycerol.

In some embodiments of the present invention, the composition further comprises proteins other than α-lactalbumin and β-casein.

In some embodiments of the present invention, proteins other than α-lactalbumin and β-casein are proteins commonly used in the art.

In some embodiments of the present invention, the protein other than α-lactalbumin and β-casein is selected from the group consisting of ovalbumin, lecithin, albumin, myosin, soybean protein, glutenin, glutenin, gliadin, Zein, glial, collagen, legumin, and milk proteins other than a-lactalbumin and beta-casein.

In some embodiments of the invention, the composition further comprises carbohydrates.

In some embodiments of the present invention, the carbohydrates are commonly used carbohydrates in the field.

In some embodiments of the present invention, the carbohydrate is selected from glucose, fructose, galactose, sucrose, lactose, maltose, starch, cellulose, hemicellulose and pectin.

In some embodiments of the present invention, the composition also includes pharmaceutical excipients and optional medicines for preventing or alleviating colic in infants, or improving the symptoms and/or behaviors of infants getting angry active ingredient, or the composition also contains food additives.

In some embodiments of the present invention, the pharmaceutical excipients are commonly used pharmaceutical excipients in this field.

In some embodiments of the present invention, pharmaceutical excipients can be selected from solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure Regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrating agents, penetration enhancers, pH regulators, buffers, plasticizers , surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculants, filter aids and release retardants.

In some embodiments of the present invention, food additives can be selected from nutritional fortifiers, antioxidants, flavor enhancers, sweeteners, thickeners, preservatives, anticaking agents and acidity regulators.

In some embodiments of the present invention, nutritional supplements can be selected from vitamins (such as vitamin A, B ₁ , B ₆ , B ₁₂ , C, D, E), minerals (such as magnesium, phosphorus, calcium, iron, zinc, Selenium or their derivatives, etc.), dietary fiber, taurine and choline.

In some embodiments of the invention, the food product is a dairy product.

In some embodiments of the present invention, every 100 grams of dairy products contains 0.5-16 g of a-lactalbumin, such as 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 11 g, 12 g, 13 g , 14g, 15g.

In some embodiments of the present invention, every 100 grams of dairy products contains 0.8-20 g of β-casein, such as 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, 11 g, 12 g, 13 g, 14 g , 15g, 16g, 17g, 18g, 19g.

In some embodiments of the present invention, the number of viable bifidobacteria per 100 grams of dairy products is 10 ⁶ to 10 ¹⁵ CFU, such as 10 ⁷ CFU, 10 ⁸ CFU, 10 ⁹ CFU, 10 ¹⁰ CFU, 10 ¹¹ CFU, 10 ¹² CFU, 10 ¹³ CFU, 10 ¹⁴ CFU.

In some embodiments of the present invention, the symptoms of getting angry in infants and young children are selected from the group consisting of red complexion, red and swollen eyes, excess eye mucus, dry lips, bad breath, mucus or yellow nose, hot hands and feet, yellow urine, thickened tongue coating, and hard stools .

In some embodiments of the present invention, the behavior of infants and young children getting angry is selected from the group consisting of waking up at night and crying, short-tempered, irritable, crying during the day, hungry more than usual, eating less than usual, fondling of quilts and not fond of wearing clothes. clothing.

In the present invention, dairy products are selected from sterilized milk, sterilized milk, reconstituted milk, yogurt, yogurt, milk powder, formula milk powder, condensed milk, cheese, casein, whey powder, milk fat and milk-containing beverages, at least One, preferably (infant) formula milk powder.

Among the present invention, if no special instructions, wherein:

The term "glyceryl palmitate" refers to fatty acid glycerides with at least one palmitic acid attached to the glyceryl group, which can be selected from monoesters, diesters, and triesters, wherein other fatty acids can also be attached to the glyceryl groups of the diesters and triesters group.

The term "Sn-2 palmitic acid" refers to palmitic acid attached to the Sn-2 position on a glyceryl group of a fat.

The term "Sn-2 palmitic acid glyceride" refers to the fatty acid glyceride of palmitic acid connected to the Sn-2 position on the glyceryl group, which can be selected from Sn-2 palmitic acid monoglyceride, Sn-2 palmitic acid diglyceride and Sn -2 palmitic acid triglyceride; Wherein, the Sn-1 position and/or Sn-3 position on the glyceryl group in Sn-2 palmitic acid triglyceride and Sn-2 palmitic acid triglyceride can be connected to any fatty acid, including but Not limited to palmitic acid, butyric acid, caproic acid, caprylic acid, capric acid, octadecanoic acid, dodecanoic acid, myristic acid, eicosic acid, myristic acid, palmitoleic acid, rapeseed acid, linoleic acid, linoleic acid Acid etc.

The term "a-whey protein" is a protein extracted from milk. It has the characteristics of high nutritional value, easy digestion and absorption, and contains a variety of active ingredients. It is one of the high-quality protein supplements for human body.

The term "β-casein" is a phosphorylated protein synthesized by mammary acinar epithelial cells, widely present in the milk of mammals (cattle, yak, goat, horse, rabbit, etc.) and human.

The beneficial effect that the present invention obtains:

The present invention provides the application of the composition in preventing, reducing or alleviating intestinal colic in infants, or in improving the symptoms and/or behaviors of infants getting angry.

Description of drawings

In order to make the content of the present invention more easily understood, the present invention will be described in further detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein

Figure 1 is a schematic diagram of the incidence of colic among infants in the test group, control group and breast milk group at different time points;

Figure 2 is a schematic diagram of the average score of the difference between the total score of the symptoms and behavioral performance of the test group, the control group and the breast milk group at each time point and the total score of the symptoms and behavioral performance at the baseline;

Figure 3 is a schematic diagram of the average score of the difference between the performance scores of angry behaviors and the scores of angry behaviors at baseline for infants in the test group, the control group and the breast milk group at each time point;

Figure 4 is a schematic diagram of the mean score of the difference between the scores of infants in the test group, the control group and the breast milk group at each time point when they wake up crying at night and at the baseline.

Detailed ways

The embodiments of the present invention will be clearly and completely described below in conjunction with the examples. Apparently, the described examples are only some of the examples of the present invention, but not all of them. The following description of at least one exemplary embodiment is merely illustrative in nature and in no way taken as limiting the invention, its application or uses. Based on the embodiments of the present invention, all other embodiments obtained by persons of ordinary skill in the art without creative efforts fall within the protection scope of the present invention.

Example

Formula milk powder was prepared according to the example formula in Table 1. About 2.17g of Sn-2 glyceryl palmitate is contained in every 100g of milk powder.

Table 1

comparative example

Formula milk powder was prepared according to the control formula in Table 1. About 0.7g of Sn-2 glyceryl palmitate is contained in every 100g of milk powder.

Clinical Experimental Methods and Experimental Results

Randomized control design, compare the feeding effect of embodiment formula and contrast formula milk powder.

1. Grouping of experimental subjects:

Infants for inclusion were screened by a pediatrician or trained researcher using a recruitment screening questionnaire. Written informed consent from the mother was required before entering the study.

1.1 Inclusion criteria

Full-term infants: gestational weeks ≥ 37 weeks;

Birth weight: 2.5kg-4kg;

Babies with normal pregnancy and delivery (including caesarean section);

Good health, Apgar score > 7 points 5-10 minutes after birth;

Age: <15 days.

1.2 Exclusion criteria

Infants with any of the following characteristics were excluded:

Congenital malformations or chromosomal diseases detected at birth with clinical significance;

Those who suffer from diseases requiring mechanical ventilation or drug treatment within one week after birth (excluding infantile jaundice patients treated with blue light);

Those who affect feeding or metabolism due to suspicious or unknown metabolic factors or body defects;

Twins or multiple births.

1.3 Experimental grouping

Full-term infants aged 0-6 months were selected as the research object, and the infants had sufficient breast milk after birth, and the mothers were willing to breastfeed until the age of 6 months, as the breast milk group; breastfeeding was not possible, and infant formula feeding was decided, 1-15 Day-old infant formula feeding amount ≥ 250ml/d, milk powder feeding greater than 80% of infants after starting intervention, are randomly divided into test group (feeding embodiment formula milk powder) and control group (feeding contrast formula milk powder). The number of participants in each group is not less than 5 people.

2. Intervention Research Methods

Baseline (15th day after birth) survey and sample collection were carried out on the enrolled infants, and then they were fed continuously for 6 months. During this period, the project researchers followed up the subjects at 4 weeks, 6 weeks, 8 weeks, 16 weeks and 24 weeks after the start of feeding. Investigate the infant's basic demographic and sociological conditions, the incidence of colic and the situation of getting angry.

3. Results of clinical trials

3.1 Basic demographic and sociological conditions of infants in different experimental groups

Comparing the infants of the three experimental groups found that the sociodemographic distributions of the test group, the breast milk group and the control group were similar, but there were slight differences in the father's work status, parents' highest education level and family income between the test group and the breast milk group. The existing literature and reports on breastfeeding and infant formula feeding usually also reflect these differences, so these differences will not hinder or affect the comparison of the results of this experiment. In addition, as shown in Table 3.1: there was no significant difference in the sex ratio of the infants in the three groups; compared with the test group and the control group, the vaginal delivery rate in the breast milk group was higher, and there was no difference in the vaginal delivery rate between the test group and the control group; The T-test p-values of the breast milk group or control group and the test group data are also provided in Table 3.1. A p-value < 0.05 indicates a statistical difference, and a p-value < 0.01 indicates a significant statistical difference.

Table 3.1 Composition of Infant Sex and Mode of Delivery

3.2 Incidence of colic among infants in different experimental groups

The incidence rate (%) of intestinal colic among infants in the three experimental groups was observed, and the results are shown in FIG. 1 .

It can be seen from Figure 1 that although the incidence of colic in the test group was higher than that in the control group at the baseline, as the feeding time was prolonged, the incidence of colic in the test group was significantly lower than that in the control group after the 6th week; Moreover, the highest incidence of colic in the test group appeared at 6-8 weeks, and then gradually decreased, which was close to the change trend of the breast milk group, while the highest incidence of colic in the control group appeared at 16 weeks, There has been no decrease, and it has brought greater pressure to the baby and the family. This shows that the formula milk powder of the present invention can effectively alleviate or improve the colic symptoms of infants and young children.

3.3 Inflammation of infants in different experimental groups

According to the theory of traditional Chinese medicine, after infants and young children get angry, they usually have red complexion, red and swollen eyes, excessive eye mucus, dry lips, bad breath (except for the smell of milk), mucus or yellow nose, hot hands and feet, yellow urine, Thickened tongue coating, hard stools, waking up at night crying, irritable, angry, crying during the day, hungry more than usual, eating less than usual, love to push the quilt, don't like to wear clothes the behavior of. Observe and score the above-mentioned symptoms and behaviors of infants in the three experimental groups at baseline (15th day after birth), 4th week, 6th week, 16th week, and 24th week. Scoring criteria: Except for stool, add one point for each symptom or behavior, and no point for absence; if the stool is watery, add one point; if the stool is soft, add two points; if the stool is soft, add one point; Slightly formed, add three points; if the stool is dry and hard, add four points; if the stool is very dry and hard, add five points. The average score of the difference between the total scores of the symptoms and behavioral performance of infants in each group at each time point and the total score of the symptoms and behavioral performance at the baseline is shown in Figure 2. The average score of the difference between the scores of angry behavior performance scores of infants in each group at each time point and the scores of baseline angry behavior performance is shown in Figure 3. The average score of the difference between the score of crying at night and the score of waking up and crying at baseline in each group of infants at each time point is shown in Figure 4.

It can be seen from Figure 2 that the infants in the test group and the control group showed similar improvements in the degree of anger compared with the baseline at the 4th week. Afterwards, with the prolongation of the feeding time, the infants in the test group gradually alleviated the degree of irritation, and the degree of irritation in the 24th week was obvious lower than the 4th week; while the infants in the control group showed a sharp increase in the degree of fire in the 4th to 6th week, and then returned to the level of the 4th week in the 8th week, and then increased in the 8th to 16th week until the 24th week It was only slightly relieved from the 4th week, but still much more severe than the 24th week of the test group infants. It can be seen from Figure 3 that the performance of the infants in the test group improved better than that of the infants in the control group in the 4th week compared with the baseline; after that, the infants in the control group showed aggravated behaviors, and the performance of the infants in the control group did not improve until the 16th to 24th week. It was relieved, but it was still much more serious than that of the infants in the test group; while the behavior of the infants in the test group gradually improved from the 4th to the 24th week, and was similar to that of the infants in the breast milk group by the 24th week. It can be seen from Figure 4 that the nighttime crying of the infants in the control group was always more serious than that of the infants in the test group. This shows that the formula milk powder of the present invention is helpful to improve the symptoms of getting angry and the performance of getting angry in infants and young children.

Apparently, the above-mentioned embodiments are only examples for clear description, rather than limiting the implementation. For those of ordinary skill in the art, other changes or changes in different forms can be made on the basis of the above description. It is not necessary and impossible to exhaustively list all the implementation manners here. And the obvious changes or changes derived therefrom are still within the scope of protection of the present invention.

Claims (8)

1. The purposes of composition in the medicine of preparation prevention or treatment infantile colic; Wherein, The composition comprises glyceryl palmitate, α-lactalbumin, β-casein, and bifidobacterium BB12 and bifidobacterium HN019; Wherein, according to the calculation of palmitic acid, glyceryl palmitate contains more than 30% weight of Sn-2 glyceryl palmitate; Wherein, in the composition, the weight ratio between α-lactalbumin, β-casein and Sn-2 glyceryl palmitate is (1-10):(1-10):(1-10); Wherein, in the composition, the number of viable bifidobacteria is 10 ⁷ to 10 ¹³ CFU per gram of a-lactalbumin; Wherein, in the composition, the ratio of the number of viable bacteria of the bifidobacterium BB12 to the bifidobacterium HN019 is (1:100)-(100:1). 2. Use according to claim 1, wherein the composition further comprises fats other than glyceryl palmitate. 3. purposes according to claim 2, wherein, the fat except glyceryl palmitate is selected from glyceryl linoleate, α-linolenic acid glyceride, docosahexaenoic acid glyceride and arachidonic acid Glycerides. 4. purposes according to claim 2, wherein, in composition, according to fatty acid calculation, glyceryl palmitate weight accounts for 20%～90% of total fat weight. 5. The use according to claim 1, wherein the composition further comprises proteins other than α-lactalbumin and β-casein. 6. The use according to claim 5, wherein the protein other than α-lactalbumin and β-casein is selected from the group consisting of ovalbumin, lecithin, albumin, muscle protein, soybean protein, glutenin, glutenin , gliadin, zein, pectin, collagen, legumin, and milk proteins other than a-lactalbumin and beta-casein. 7. The use according to claim 1, wherein the composition further comprises carbohydrates. 8. The use according to claim 7, wherein the carbohydrate is selected from the group consisting of glucose, fructose, galactose, sucrose, lactose, maltose, starch, cellulose, hemicellulose and pectin.

Images